ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 75.88 USD | +0.53% |
|
+7.10% | +12.67% |
| Sales 2024 * | 51.24B 4,275B | Sales 2025 * | 54.8B 4,572B | Capitalization | 234B 19,541B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.52B 711B | Net income 2025 * | 10.2B 851B | EV / Sales 2024 * | 4.96 x |
| Net Debt 2024 * | 19.9B 1,660B | Net Debt 2025 * | 13.44B 1,121B | EV / Sales 2025 * | 4.52 x |
| P/E ratio 2024 * |
27.8
x | P/E ratio 2025 * |
23.3
x | Employees | 89,900 |
| Yield 2024 * |
2.06% | Yield 2025 * |
2.14% | Free-Float | 96.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More press releases
| 1 day | +0.53% | ||
| 1 week | +7.10% | ||
| 1 month | +12.00% | ||
| 3 months | +13.87% | ||
| 6 months | +20.01% | ||
| Current year | +12.67% |
1 week
74.50
76.58
1 month
66.3976.58
Current year
60.4776.58
1 year
60.4776.58
3 years
52.6576.58
5 years
36.1576.58
10 years
25.5576.58
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 01/12/01 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 01/21/01 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 01/20/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 01/17/01 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 01/13/01 |
Philip Broadley
BRD | Director/Board Member | 63 | 27/17/27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.38% | 9 M€ | -4.31% | - | |
| 0.99% | 1,182 M€ | -0.33% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 75.88 | +0.53% | 8,547,320 |
| 29/24/29 | 75.48 | +0.41% | 7,538,322 |
| 26/24/26 | 75.17 | +0.19% | 6,687,969 |
| 25/24/25 | 75.03 | +5.38% | 15,606,581 |
| 24/24/24 | 71.2 | +0.49% | 6,137,682 |
Delayed Quote Nasdaq, April 01, 2024 at 01:30 am IST
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
21/05/2024
- Investor Day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
151.1
USD
Average target price
164.3
USD
Spread / Average Target
+8.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +34.00% | 664B | |
| +29.29% | 567B | |
| -7.75% | 354B | |
| +18.53% | 330B | |
| +4.95% | 286B | |
| +4.93% | 199B | |
| -9.78% | 196B | |
| -4.89% | 148B | |
| -11.01% | 145B |
- Stock Market
- Equities
- AZN Stock
- AZN Stock
